Immune cellular subpopulations in BC representing the innate immunity (natural killer, CD68+ and CD11c+ cells) and adaptive immunity (CD3+ cells (CD8+ or CD4+) and CD20+ cells) [38], worth thorough evaluation in TNBC, with the aim of understanding its clinical implications in BC management. The gene discussed is ITGAX; the disease is breast cancer.